Q&A: Forbion Capital Partners' Sander Slootweg
Life-sciences-focused venture firm Forbion Capital Partners recently held a €360m final close for its fourth flagship fund, surpassing its initial hard-cap of €350m. Managing partner Sander Slootweg speaks to Francesca Veronesi about the fundraising process, the firm's 'build' strategy and the European life sciences venture market
More on Benelux
Digital doctors here to stay as telemedicine deals surge
Rise in demand for telemedicine – and promising returns for investors that have been targeting the space – looks set to continue
Egeria invests in Apoc Aviation
Deal is an exit for minority shareholder Antea, which invested in the company in 2015
Nordian Capital completes J-Club acquisition
Deal follows M&A litigation initiated after coronavirus uncertainty and financing difficulties
Amplify raises $375m across two funds
Amplify IV targets seed and series-A rounds, while Amplify Select makes follow-on investments in existing portfolio companies
Latest News
Digital doctors here to stay as telemedicine deals surge
Rise in demand for telemedicine – and promising returns for investors that have been targeting the space – looks set to continue
Investindustrial exits Aston Martin
Investindustrial sells its remaining stake of 4.12% in the company, fully exiting the investment
PE-backed Nets bolts on CCV Schweiz
Following the deal, CCV Schweiz will be integrated with Concardis Schweiz, which is part of Nets Group
VC-backed Getnow files for insolvency
Minority shareholder IMS Capital has also filed for insolvency; Getnow is now seeking new investors